Track Record

Specifically, Numedicus has used drug repurposing to found and help to develop valuable intellectual property around clinical stage developments for various pharmaceutical and biotechnology companies in the following manner:

  • MT-102, a Phase II development candidate for the treatment of cancer cachexia, with a successful outcome reported by PsiOxus
  • REV-001, licensed to Revive Therapeutics Inc., reported success in an early clinical trial for the prevention of opiate-induced respiratory depression (without affecting analgesia). Has additionally been shown to be highly effective in a gold-standard animal model of Rett Sydrome.
  • DDP225, a development stage product provided to Dynogen and successfully trialled in Phase IIa for d-IBS.

In addition to these successes, over the past decade, the Company used its discovery engine to identify and develop deep and rich pipeline for a variety of clients, initially for Arachnova Therapeutics Limited, but also for various Drug Delivery Companies (UK and European). Overall, the therapeutic areas in which the Company has made therapeutic switch proposals include a wide range:

acute myocardial infarction fibromyalgia nociceptive pain

cachexia functional bowel disease overactive bladder

diabetic retinopathy stress incontinence premature ejaculation

Dupuytren’s contracture cancer fatigue pulmonary hypertension

nausea and vomiting glaucoma reperfusion injury

Raynaud’s phenomenon hypertrophic scarring restenosis

retinal ischaemia leg ulcers rosacea

female anorgasmia neuropathic pain scleroderma
acute lung injury acute rejection of lung xenograft wound healing

An example of what we have done recently, in more detail, is shown on the next two pages.